Current approaches to treating Alzheimer's disease

Anti-Aβ antibodies decreased cognitive loss by a mean of 26%.

• Alzheimer's disease progresses through three phases involving beta-amyloid deposits, tau tangles, and subsequent neuronal damage.
• Monoclonal antibodies targeting beta-amyloid and tau proteins have shown potential in reducing the burden of these pathogenic proteins in the brain.
• Anti-p-tau antibodies did not demonstrate any effect on cognitive loss despite being well-tolerated.
• 30% of patients treated with anti-Aβ antibodies experienced brain swelling and hemorrhages as detected by imaging.
• Investigations into pharmacological interventions targeting phase III mechanisms include various approaches to enhance neuronal resilience.

Simplified